Evidence map›Paper›PMID 32253449›Full record

ArticleIntensive care medicine2020

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Qiurong Ruan, Kun Yang, Wenxia Wang, Lingyu Jiang, Jianxin Song

4 registry-linked trialsAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 109 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04400929 phase2completednot on this map

Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial

TypeinterventionalSponsorSingapore General HospitalRan2020 to 2022Enrolled2ConditionsCOVID, Sars-CoV2, ARDS, HumanArmsSargramostim, Normal Saline 0.9%
NCT04494724 phase2recruitingnot on this map

A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection

TypeinterventionalSponsorThe Methodist Hospital Research InstituteRan2020 to 2021Enrolled60ConditionsCOVID-19 InfectionArmsClazakizumab, Placebo
NCT04594356 completednot on this map

Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2020 to 2023Enrolled120ConditionsCovid19
NCT04798716 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19 Positive Patients With Acute Respiratory Distress Syndrome and/or Novel Coronavirus Pneumonia

TypeinterventionalSponsorAVEM HealthCareRan2023 to 2024Enrolled55ConditionsCovid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress SyndromeArmsMSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Postorotracheal intubation dysphagia in patients with COVID-19: A retrospective study.Sao Paulo medical journal = Revista paulista de medicina · 2024
    Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Qiurong RuanInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0002-7015-7666
Kun YangDepartment of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0001-6729-2552
Wenxia WangDepartment of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0003-4369-6661
Lingyu JiangDepartment of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0002-2072-0107
Jianxin SongDepartment of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China. songsingsjx@sina.com.ORCID http://orcid.org/0000-0002-4090-6670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Identifiers

PMID32253449
PMCPMC7131986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.